A Phase II Trial Of Paricalcitol In Myelodysplastic Syndromes
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Leukemia
- Sponsor
- Cedars-Sinai Medical Center
- Locations
- 1
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
RATIONALE: Paricalcitol is a form of vitamin D that may help myelodysplastic cells develop into normal bone marrow cells.
PURPOSE: Phase II trial to study the effectiveness of paricalcitol in treating patients who have myelodysplastic syndrome.
Detailed Description
OBJECTIVES: * Determine the clinical effects of paricalcitol in patients with myelodysplastic syndromes. * Determine whether this drug can improve RBC, WBC, or platelet counts in these patients. * Determine whether this drug can decrease the risk of development of leukemia without causing undue toxicity in these patients. OUTLINE: Patients receive oral paricalcitol daily for 4 months in the absence of disease progression or unacceptable toxicity. Patients are followed at 1 month. PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study within 8 months.
Investigators
H. Phillip Koeffler
Director, Medicine / Hematology/Oncology
Cedars-Sinai Medical Center
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified